U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Adenocarcinoma with Neuroendocrine Differentiation

MedGen UID:
224758
•Concept ID:
C1266088
•
Neoplastic Process
Synonyms: Adenocarcinoma with neuroendocrine differentiation; Carcinoma with neuroendocrine differentiation
SNOMED CT: Carcinoma with neuroendocrine differentiation (128704005); Adenocarcinoma with neuroendocrine differentiation (128704005)

Definition

An invasive adenocarcinoma characterized by the presence of focal or extensive neuroendocrine differentiation. [from NCI]

Professional guidelines

PubMed

Lung adenocarcinoma with neuroendocrine differentiation: Molecular markers testing and treatment outcomes.
Chang HC, Chen KY, Chang YL, Shih JY, Yu CJ
J Formos Med Assoc 2023 Aug;122(8):731-737. Epub 2022 Dec 30 doi: 10.1016/j.jfma.2022.12.011. PMID: 36586785

Recent clinical studies

Etiology

Treatment indicators and prognostic factors in colorectal neuroendocrine neoplasms and adenocarcinoma with neuroendocrine differentiation: a single center retrospective study.
Fu X, Wang C, Yu Y, Chen HN
Int J Colorectal Dis 2024 Oct 22;39(1):170. doi: 10.1007/s00384-024-04731-7. PMID: 39436458Free PMC Article
(18) F-FDG PET/CT imaging in neuroendocrine prostate cancer: Relation to histopathology and prognosis.
Shen K, Yu M, Ji Y, Zhou X, Liu B, Zhang W, Su R, Qi J, Wang Q, Xue W
Prostate 2023 Sep;83(12):1167-1175. Epub 2023 May 15 doi: 10.1002/pros.24559. PMID: 37189301
Lung adenocarcinoma with neuroendocrine differentiation: Molecular markers testing and treatment outcomes.
Chang HC, Chen KY, Chang YL, Shih JY, Yu CJ
J Formos Med Assoc 2023 Aug;122(8):731-737. Epub 2022 Dec 30 doi: 10.1016/j.jfma.2022.12.011. PMID: 36586785
The Colorful Palette of Neuroendocrine Neoplasms in the Genitourinary Tract.
Pósfai B, Kuthi L, Varga L, Laczó I, Révész J, Kránicz R, Maráz A
Anticancer Res 2018 Jun;38(6):3243-3254. doi: 10.21873/anticanres.12589. PMID: 29848671
Gastric adenocarcinoma with neuroendocrine differentiation: Clinicopathological features and efficacy of modified DCF chemotherapy.
Bozkaya Y, Ozdemir N, Colak A, Zengin N
J BUON 2017 Jul-Aug;22(4):919-925. PMID: 29155521

Diagnosis

Lung adenocarcinoma with neuroendocrine differentiation: Molecular markers testing and treatment outcomes.
Chang HC, Chen KY, Chang YL, Shih JY, Yu CJ
J Formos Med Assoc 2023 Aug;122(8):731-737. Epub 2022 Dec 30 doi: 10.1016/j.jfma.2022.12.011. PMID: 36586785
The Colorful Palette of Neuroendocrine Neoplasms in the Genitourinary Tract.
Pósfai B, Kuthi L, Varga L, Laczó I, Révész J, Kránicz R, Maráz A
Anticancer Res 2018 Jun;38(6):3243-3254. doi: 10.21873/anticanres.12589. PMID: 29848671
Gastric adenocarcinoma with neuroendocrine differentiation: Clinicopathological features and efficacy of modified DCF chemotherapy.
Bozkaya Y, Ozdemir N, Colak A, Zengin N
J BUON 2017 Jul-Aug;22(4):919-925. PMID: 29155521
Vulvar Adenocarcinoma With Neuroendocrine Differentiation: A Case Report.
Gabrilovich S, Cracchiolo B, Heller DS
J Low Genit Tract Dis 2017 Apr;21(2):e23-e25. doi: 10.1097/LGT.0000000000000294. PMID: 28157827
Metastatic prostatic adenocarcinoma with neuroendocrine differentiation to meningioma.
Guraya SS, Prayson RA
J Clin Neurosci 2016 Dec;34:30-32. Epub 2016 Aug 5 doi: 10.1016/j.jocn.2016.06.004. PMID: 27503809

Therapy

Transformation of NSCLC to SCLC harboring EML4-ALK fusion with V1180L mutation after alectinib resistance and response to lorlatinib: A case report and literature review.
Lingling X, Maoxi C, Wei Y, Jieting Z, Yuanyuan Y, Ning X
Lung Cancer 2023 Dec;186:107415. Epub 2023 Oct 28 doi: 10.1016/j.lungcan.2023.107415. PMID: 37907052
Lung adenocarcinoma with neuroendocrine differentiation: Molecular markers testing and treatment outcomes.
Chang HC, Chen KY, Chang YL, Shih JY, Yu CJ
J Formos Med Assoc 2023 Aug;122(8):731-737. Epub 2022 Dec 30 doi: 10.1016/j.jfma.2022.12.011. PMID: 36586785
Emergence of NOTCH2-NTRK1 After Osimertinib in a Patient With Lung Adenocarcinoma With Neuroendocrine Differentiation.
Lin G, Liu Y, Li H, Chen S, Guo Y
Clin Lung Cancer 2021 Sep;22(5):e712-e715. Epub 2021 Feb 3 doi: 10.1016/j.cllc.2021.01.015. PMID: 33714692
Emergence of NOTCH2-NTRK1 After Osimertinib in a Patient With Lung Adenocarcinoma With Neuroendocrine Differentiation.
Lin G, Liu Y, Li H, Chen S, Guo Y
Clin Lung Cancer 2021 Mar;22(2):e157-e159. Epub 2020 Oct 15 doi: 10.1016/j.cllc.2020.10.003. PMID: 33158763
Gastric adenocarcinoma with neuroendocrine differentiation: Clinicopathological features and efficacy of modified DCF chemotherapy.
Bozkaya Y, Ozdemir N, Colak A, Zengin N
J BUON 2017 Jul-Aug;22(4):919-925. PMID: 29155521

Prognosis

Transformation of NSCLC to SCLC harboring EML4-ALK fusion with V1180L mutation after alectinib resistance and response to lorlatinib: A case report and literature review.
Lingling X, Maoxi C, Wei Y, Jieting Z, Yuanyuan Y, Ning X
Lung Cancer 2023 Dec;186:107415. Epub 2023 Oct 28 doi: 10.1016/j.lungcan.2023.107415. PMID: 37907052
(18) F-FDG PET/CT imaging in neuroendocrine prostate cancer: Relation to histopathology and prognosis.
Shen K, Yu M, Ji Y, Zhou X, Liu B, Zhang W, Su R, Qi J, Wang Q, Xue W
Prostate 2023 Sep;83(12):1167-1175. Epub 2023 May 15 doi: 10.1002/pros.24559. PMID: 37189301
The Colorful Palette of Neuroendocrine Neoplasms in the Genitourinary Tract.
Pósfai B, Kuthi L, Varga L, Laczó I, Révész J, Kránicz R, Maráz A
Anticancer Res 2018 Jun;38(6):3243-3254. doi: 10.21873/anticanres.12589. PMID: 29848671
Gastric adenocarcinoma with neuroendocrine differentiation: Clinicopathological features and efficacy of modified DCF chemotherapy.
Bozkaya Y, Ozdemir N, Colak A, Zengin N
J BUON 2017 Jul-Aug;22(4):919-925. PMID: 29155521
Neuroendocrine differentiation in sporadic CRC and hereditary nonpolyosis colorectal cancer.
Sun MH
Dis Markers 2004;20(4-5):283-8. doi: 10.1155/2004/379053. PMID: 15528794Free PMC Article

Clinical prediction guides

Revisiting ALK (D5F3) immunohistochemistry: Insights into focal staining and neuroendocrine differentiation.
Sung YE, Kim M
Thorac Cancer 2024 Oct;15(30):2175-2184. Epub 2024 Sep 10 doi: 10.1111/1759-7714.15445. PMID: 39257160Free PMC Article
(18) F-FDG PET/CT imaging in neuroendocrine prostate cancer: Relation to histopathology and prognosis.
Shen K, Yu M, Ji Y, Zhou X, Liu B, Zhang W, Su R, Qi J, Wang Q, Xue W
Prostate 2023 Sep;83(12):1167-1175. Epub 2023 May 15 doi: 10.1002/pros.24559. PMID: 37189301
Dermatomyositis associated with prostate adenocarcinoma with neuroendocrine differentiation.
Minagawa H, Kawai T, Matsumoto A, Makino K, Sato Y, Nagasaka K, Tokura M, Tanaka N, Ito E, Yamada Y, Nakamura M, Yamada D, Suzuki M, Murata T, Kume H
BMC Urol 2021 Jan 7;21(1):8. doi: 10.1186/s12894-020-00779-z. PMID: 33413292Free PMC Article
Low-serum prostate-specific antigen level predicts poor outcomes in patients with primary neuroendocrine prostate cancer.
Wang J, Xu W, Mierxiati A, Huang Y, Wei Y, Lin G, Dai B, Freedland SJ, Qin X, Zhu Y, Ye DW
Prostate 2019 Sep;79(13):1563-1571. Epub 2019 Aug 2 doi: 10.1002/pros.23878. PMID: 31376193
EGFR mediates activation of RET in lung adenocarcinoma with neuroendocrine differentiation characterized by ASCL1 expression.
Bhinge K, Yang L, Terra S, Nasir A, Muppa P, Aubry MC, Yi J, Janaki N, Kovtun IV, Murphy SJ, Halling G, Rahi H, Mansfield A, de Andrade M, Yang P, Vasmatzis G, Peikert T, Kosari F
Oncotarget 2017 Apr 18;8(16):27155-27165. doi: 10.18632/oncotarget.15676. PMID: 28460442Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...